Cargando…

Current pharmacotherapy of overactive bladder

Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreydin, Evgenyi I., Gomes, Cristiano M., Cruz, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Urologia 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486454/
https://www.ncbi.nlm.nih.gov/pubmed/34003613
http://dx.doi.org/10.1590/S1677-5538.IBJU.2021.99.12
_version_ 1784577741642792960
author Kreydin, Evgenyi I.
Gomes, Cristiano M.
Cruz, Francisco
author_facet Kreydin, Evgenyi I.
Gomes, Cristiano M.
Cruz, Francisco
author_sort Kreydin, Evgenyi I.
collection PubMed
description Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment of OAB. Each drug has specific pharmacologic properties, dosing schedule and tolerability profile, making it essential to individualize the medical treatment for the patient's characteristics and expectations. In this manuscript, we review the most important factors involved in the contemporary pharmacological treatment of OAB.
format Online
Article
Text
id pubmed-8486454
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sociedade Brasileira de Urologia
record_format MEDLINE/PubMed
spelling pubmed-84864542021-10-03 Current pharmacotherapy of overactive bladder Kreydin, Evgenyi I. Gomes, Cristiano M. Cruz, Francisco Int Braz J Urol Review Article Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment of OAB. Each drug has specific pharmacologic properties, dosing schedule and tolerability profile, making it essential to individualize the medical treatment for the patient's characteristics and expectations. In this manuscript, we review the most important factors involved in the contemporary pharmacological treatment of OAB. Sociedade Brasileira de Urologia 2021-05-10 /pmc/articles/PMC8486454/ /pubmed/34003613 http://dx.doi.org/10.1590/S1677-5538.IBJU.2021.99.12 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kreydin, Evgenyi I.
Gomes, Cristiano M.
Cruz, Francisco
Current pharmacotherapy of overactive bladder
title Current pharmacotherapy of overactive bladder
title_full Current pharmacotherapy of overactive bladder
title_fullStr Current pharmacotherapy of overactive bladder
title_full_unstemmed Current pharmacotherapy of overactive bladder
title_short Current pharmacotherapy of overactive bladder
title_sort current pharmacotherapy of overactive bladder
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486454/
https://www.ncbi.nlm.nih.gov/pubmed/34003613
http://dx.doi.org/10.1590/S1677-5538.IBJU.2021.99.12
work_keys_str_mv AT kreydinevgenyii currentpharmacotherapyofoveractivebladder
AT gomescristianom currentpharmacotherapyofoveractivebladder
AT cruzfrancisco currentpharmacotherapyofoveractivebladder